Low Oral Bioavailability of RPL554, a First-in-Class Dual PDE3/4 Inhibitor, Demonstrates that Its Nebulized, Inhaled Formulation Is Appropriate for Delivering Optimal Pulmonary Dose

被引：0
|
作者：
Newman, K. B. [1 ]
Armstrong, M. [2 ]
Maurer, B. T. [3 ]
Ayrton, J. [1 ]
Causon, R. [1 ]
机构：
[1] Verona Pharma, London, England
[2] Quintiles IMS, Quintiles Phase Serv 1, Overland Pk, KS USA
[3] Verona Pharma Plc, White Plains, NY USA
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2018年 / 197卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A3022
引用
收藏
页数：1
相关论文
共 11 条
  • [1] Safety And Bronchodilator Effects Of Nebulized Rpl554, A Novel Dual Pde3/4 Inhibitor In COPD
    Cazzola, M.
    Calzetta, L.
    Segreti, A.
    Rogliani, P.
    Page, C.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2013, 187
  • [2] Anti-inflammatory effect of a novel inhaled dual PDE3/4 inhibitor RPL554 in man, a unique "first-in-class" drug for the treatment of COPD & asthma
    Singh, Dave
    Reid, Fred
    Franciosi, Lui
    Walker, Michael
    Page, Clive
    EUROPEAN RESPIRATORY JOURNAL, 2013, 42
  • [3] Ensifentrine (RPL554): an inhaled "bifunctional' dual PDE3/4 inhibitor for the treatment of asthma and chronic obstructive pulmonary disease
    Cazzola, Mario
    Page, Clive
    Calzetta, Luigino
    Matera, Maria Gabriella
    PHARMACEUTICAL PATENT ANALYST, 2018, 7 (06) : 249 - 257
  • [4] RPL554, A First-In-Class Dual PDE3/4 Inhibitor, Causes Rapid Additional Bronchodilation When Dosed with Tiotropium in COPD Patients
    Newman, K. B.
    Singh, D.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
  • [5] Bronchodilator effect of a novel inhaled dual PDE3/4 inhibitor, RPL554, in mild allergic asthma & rhinitis
    Diamant, Zuzana
    Franciosi, Lui
    Morelli, Nicoletta
    Zuiker, Rob
    Kamerling, Ingrid
    de Kam, Marieke
    Burggraaf, Koos
    Cohen, Adam
    Walker, Michael
    Page, Clive
    EUROPEAN RESPIRATORY JOURNAL, 2013, 42
  • [6] RPL554, an inhaled PDE3/4 inhibitor, causes comparable bronchodilation to high dose nebulised salbutamol in asthmatics with fewer systemic effects
    Bjermer, Leif
    Stewart, Johnston
    Abbott-Banner, Katharine
    Newman, Kenneth
    EUROPEAN RESPIRATORY JOURNAL, 2016, 48
  • [7] Rpl554, A First-In-Class Dual Phosphodiesterase (pde)3/4 Inhibitor, Is Equi-Effective As A Bronchodilator To Maximal Doses Of Salbutamol In Asthmatics But With Fewer Adverse Events
    Bjermer, L.
    Stewart, J.
    Abbott-Banner, K. H.
    Newman, K.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193
  • [8] Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials
    Franciosi, Lui G.
    Diamant, Zuzana
    Banner, Katharine H.
    Zuiker, Rob
    Morelli, Nicoletta
    Kamerling, Ingrid M. C.
    de Kam, Marieke L.
    Burggraaf, Jacobus
    Cohen, Adam F.
    Cazzola, Mario
    Calzetta, Luigino
    Singh, Dave
    Spina, Domenico
    Walker, Michael J. A.
    Page, Clive P.
    LANCET RESPIRATORY MEDICINE, 2013, 1 (09): : 714 - 727
  • [9] Late Breaking Abstract-RPL554, a first-in-class dual PDE3/4 inhibitor, causes significant bronchodilation and symptom relief; a Phase 2b COPD study
    Maurer, Brian
    Singh, Dave
    Martinez, Fernando
    Newman, Kenneth
    EUROPEAN RESPIRATORY JOURNAL, 2018, 52
  • [10] LATE-BREAKING ABSTRACT: The novel inhaled dual PDE3/4 inhibitor RPL554 produces significant additional improvements in lung function when administered on top of existing standard of care in COPD patients
    Singh, Dave
    Abbott-Banner, Katharine
    Newman, Kenneth
    EUROPEAN RESPIRATORY JOURNAL, 2016, 48
12